| Inovio Pharmaceuticals, Inc. (INO) Q1 2025 Earnings Call Transcript |
Inovio Pharmaceuticals, Inc. (NASDAQ:INO ) Q1 2025 Earnings Conference Call May 13, 2025 4:30 PM ET Company Participants Jennie Willson - IR Jacqui Shea - President & CEO Mike Sumner - Chief Medical Officer Steve Egge - Chief Commercial Officer Peter Kies - CFO Conference Call Participants Roy Buchanan - Citizens JMP Jay Olson - Oppenheimer Sudan Loganathan - Stephens Roger Song - Jefferies Yi Chen - H.C. Wainwright Operator Good afternoon, ladies and gentlemen, and welcome to the Inovio First Quarter 2025 Financial Results Conference Call. |
seekingalpha.com |
2025-05-13 23:05:33 |
Czytaj oryginał (ang.) |
| Inovio Pharmaceuticals (INO) Reports Q1 Loss, Tops Revenue Estimates |
Inovio Pharmaceuticals (INO) came out with a quarterly loss of $0.51 per share versus the Zacks Consensus Estimate of a loss of $0.74. This compares to loss of $1.31 per share a year ago. |
zacks.com |
2025-05-13 22:40:33 |
Czytaj oryginał (ang.) |
| INOVIO Reports First Quarter 2025 Financial Results and Recent Business Highlights |
On track to begin rolling submission of Biologics License Application (BLA) for INO-3107 as a potential treatment for recurrent respiratory papillomatosis (RRP) in mid-2025 Device design verification (DV) testing of CELLECTRA device required for BLA submission is underway, anticipated completion in 1H25 Clinical and immunological results from Phase 1/2 trial of INO-3107 published in Nature Communications in February 2025 INO-3107 induced new populations of T cells in the blood that traveled to airway tissue and were associated with significant clinical benefit as measured by reduced need for surgery Announced promising interim results from ongoing proof-of-concept Phase 1 trial showing DNA-encoded monoclonal antibodies (DMAbs) were well tolerated and exhibited long-lasting in vivo production Preprint manuscript available on ResearchSquare.com PLYMOUTH MEETING, Pa. , May 13, 2025 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced its financial results for the first quarter of 2025 and provided an update on recent company developments. |
prnewswire.com |
2025-05-13 20:05:00 |
Czytaj oryginał (ang.) |
| Inovio Pharmaceuticals, Inc. (INO) Citizens JMP Life Sciences Conference (Transcript) |
Inovio Pharmaceuticals, Inc. (NASDAQ:INO ) Citizens JMP Life Sciences Conference May 8, 2025 11:30 AM ET Company Participants Jacqui Shea - President and CEO Mike Sumner - Chief Medical Officer Conference Call Participants Roy Buchanan - JMP Roy Buchanan All right. Thank you again, everybody, for joining us here at the Citizens Life Sciences Conference. |
seekingalpha.com |
2025-05-09 23:37:13 |
Czytaj oryginał (ang.) |
| INOVIO to Present at Upcoming Scientific and Investor Conferences |
PLYMOUTH MEETING, Pa. , April 30, 2025 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it will be presenting at several upcoming conferences, including a fireside chat at the Citizens JMP Life Sciences Conference in New York. |
prnewswire.com |
2025-04-30 12:05:00 |
Czytaj oryginał (ang.) |
| INOVIO to Report First Quarter 2025 Financial Results on May 13, 2025 |
PLYMOUTH MEETING, Pa. , April 29, 2025 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancers, and infectious diseases, today announced that first quarter 2025 financial results will be released after the market close on May 13, 2025. |
prnewswire.com |
2025-04-29 12:05:00 |
Czytaj oryginał (ang.) |
| Bet on These 5 Top-Ranked Stocks With Rising P/E |
Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach. These stocks include Carvana, Context Therapeutics Inc, Inovio Pharmaceuticals, ChargePoint and MSA Safety Inc. |
zacks.com |
2025-04-21 12:40:36 |
Czytaj oryginał (ang.) |
| Inovio (INO) Upgraded to Buy: Here's What You Should Know |
Inovio (INO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. |
zacks.com |
2025-04-09 17:00:41 |
Czytaj oryginał (ang.) |
| INOVIO to Present at Upcoming Scientific Conferences |
PLYMOUTH MEETING, Pa. , April 9, 2025 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it will highlight key data associated with its lead candidate, INO-3107, at several upcoming conferences, including an opportunity to join other leading voices at the inaugural National HPV Conference. |
prnewswire.com |
2025-04-09 12:05:00 |
Czytaj oryginał (ang.) |
| Down -11.41% in 4 Weeks, Here's Why You Should You Buy the Dip in Inovio (INO) |
Inovio (INO) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock. |
zacks.com |
2025-04-01 14:35:38 |
Czytaj oryginał (ang.) |
| Inovio Pharmaceuticals, Inc. (INO) Q4 2024 Earnings Call Transcript |
Inovio Pharmaceuticals, Inc. (NASDAQ:INO ) Q4 2024 Earnings Conference Call March 18, 2025 4:30 PM ET Company Participants Jennie Willson - IR Jacqui Shea - President & CEO Mike Sumner - Chief Medical Officer Steve Egge - Chief Commercial Officer Peter Kies - CFO Conference Call Participants Roy Buchanan - Citizens JMP Jay Olson - Oppenheimer Sudan Loganathan - Stephens Yi Chen - H.C. Wainwright Anish Nikhanj - RBC Liang Cheng - Jefferies Operator Good afternoon, ladies and gentlemen, and welcome to the Inovio Pharmaceuticals Fourth Quarter 2024 Financial Results Conference Call. |
seekingalpha.com |
2025-03-18 22:48:01 |
Czytaj oryginał (ang.) |
| INOVIO Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights |
Significant progress toward submitting a biologics license application (BLA) for INO-3107 as a potential treatment for recurrent respiratory papillomatosis (RRP) Resolved previously announced manufacturing issue concerning the single-use array component of the CELLECTRA device and completed drafting of all non-device BLA modules On track to begin rolling submission of BLA in mid-2025 and to request priority review with goal of completing the submission in the second half of 2025 and receiving acceptance of the submission by end of the year Announced durability data from retrospective study showing that 50% of patients achieved a Complete Response in the second 12-month period (year 2) with 86% of patients showing a reduction in surgery of 50% or greater in year 2; data to be included in BLA submission Announced promising interim results from ongoing proof-of-concept Phase 1 trial showing DNA-encoded monoclonal antibodies (DMAb) targeting COVID-19 were well tolerated and exhibited long-lasting in vivo production DMAb technology has the potential to overcome traditional monoclonal antibody production challenges, such as short half-life and anti-drug immune responses, making it a potentially promising platform for a broad range of diseases DNA Medicine technology has the potential to provide long term production of therapeutic antibodies and deliver a broad spectrum of therapeutic proteins that could be used to treat diseases with missing or defective proteins PLYMOUTH MEETING, Pa. , March 18, 2025 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced its financial results and operational highlights for the fourth quarter and full year ended December 31, 2024 and provided a business update and description of operational highlights during the year. |
prnewswire.com |
2025-03-18 18:05:00 |
Czytaj oryginał (ang.) |
| INOVIO Announces Promising Interim Results from Ongoing Proof-of-Concept Clinical Trial of DNA-Encoded Monoclonal Antibodies (DMAbs) for COVID-19 |
Long-lasting in vivo antibody production: DMAb levels remained stable for 72 weeks in all participants (n=24) who have reached that timepoint No anti-drug antibodies (ADA): no immune rejection of the DMAbs was detected across ~1,000 blood samples, unlike other gene-based antibody delivery approaches where ADA formation has been a challenge Well-tolerated: most common side effects were mild, temporary injection site reactions such as pain and redness; no serious adverse events (SAEs) related to study drug Effective target binding: expressed DMAbs successfully bound to the SARS-CoV-2 Spike protein receptor-binding domain (RBD), confirming functional activity through week 72 PLYMOUTH MEETING, Pa. , March 13, 2025 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced promising interim results from an ongoing Phase 1 proof-of-concept trial evaluating DMAbs for COVID-19. |
prnewswire.com |
2025-03-13 20:15:00 |
Czytaj oryginał (ang.) |
| INOVIO to Report Fourth Quarter and Year End 2024 Financial Results on March 18, 2025 |
PLYMOUTH MEETING, Pa. , March 12, 2025 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancers, and infectious diseases, today announced that fourth quarter and year-end 2024 financial results will be released after the market close on March 18, 2025. |
prnewswire.com |
2025-03-12 14:55:00 |
Czytaj oryginał (ang.) |
| Inovio Pharmaceuticals Inc (INO) Oppenheimer 35th Annual Healthcare Life Sciences Conference (Transcript) |
Inovio Pharmaceuticals Inc (NASDAQ:INO ) Oppenheimer 35th Annual Healthcare Life Sciences Conference February 12, 2025 3:20 PM ET Company Participants Jacqui Shea - CEO and President Conference Call Participants Jay Olson - Oppenheimer Jay Olson And our discussion with Inovio. It's a pleasure to introduce Jacqui Shea, CEO and President. |
seekingalpha.com |
2025-02-12 19:39:03 |
Czytaj oryginał (ang.) |
| Here's Why Inovio (INO) Could be Great Choice for a Bottom Fisher |
Inovio (INO) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term. |
zacks.com |
2025-02-12 12:55:24 |
Czytaj oryginał (ang.) |
| Clinical and Immunological Results from Phase 1/2 Study of INO-3107 as a Treatment for Recurrent Respiratory Papillomatosis Published in Nature Communications |
Data shows that INO-3107 induced new populations of T cells in the blood that traveled to airway tissue and were associated with clinical benefit as measured by reduced need for surgeries PLYMOUTH MEETING, Pa. , Feb. 12, 2025 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that peer-reviewed data from its Phase 1/2 clinical trial with INO-3107 as a potential treatment for recurrent respiratory papillomatosis (RRP) were published online in Nature Communications under the title DNA immunotherapy for recurrent respiratory papillomatosis (RRP): phase 1/2 study assessing efficacy, safety, and immunogenicity of INO-3107. |
prnewswire.com |
2025-02-12 10:00:00 |
Czytaj oryginał (ang.) |
| Immune Response Data for INO-3107 to be Presented as a Poster at American Association for Cancer Research Immuno-Oncology (AACR-IO) Conference |
Poster will describe loss of detectable HPV-6 in Recurrent Respiratory Papillomatosis patients following treatment with INO-3107 PLYMOUTH MEETING, Pa. , Feb. 10, 2025 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that an abstract describing the immunological activity of INO-3107 will be presented as a poster at the following scientific conference: American Association for Cancer Research – Immuno-Oncology Discovery and Innovation in Cancer Immunology: Revolutionizing Treatment through Immunotherapy (February 23-26, 2025) Poster entitled: "Loss of Detectable HPV-6 Following Induction of Emergent T cells in Patients with Durable Complete Clinical Response to Treatment for Recurrent Respiratory Papillomatosis using INO-3107" The abstract will be made available on INOVIO's website following the conference. |
prnewswire.com |
2025-02-10 10:05:00 |
Czytaj oryginał (ang.) |
| INOVIO to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference |
PLYMOUTH MEETING, Pa. , Jan. 29, 2025 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer and infectious diseases, today announced that Dr. Jacqueline Shea, INOVIO's President and CEO, and Dr. Michael Sumner, Chief Medical Officer, will be presenting at the Oppenheimer 35th Annual Healthcare Life Sciences Conference. |
prnewswire.com |
2025-01-29 18:14:00 |
Czytaj oryginał (ang.) |
| INOVIO Highlights Anticipated 2025 Milestones and 2024 Key Accomplishments |
PLYMOUTH MEETING, Pa. , Jan. 9, 2025 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today highlighted anticipated milestones for 2025 and key accomplishments from 2024 in advance of upcoming investor meetings. |
prnewswire.com |
2025-01-09 10:04:00 |
Czytaj oryginał (ang.) |
| Gold Down Over 1%; Inovio Pharmaceuticals Shares Plummet |
U.S. stocks traded mixed toward the end of trading, with the S&P 500 edging lower on Friday. |
benzinga.com |
2024-12-13 16:10:57 |
Czytaj oryginał (ang.) |
| INOVIO Announces Pricing of $30 Million Public Offering |
PLYMOUTH MEETING, Pa. , Dec. 13, 2024 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced the pricing of an underwritten public offering of 10,000,000 shares of its common stock and accompanying warrants to purchase 10,000,000 shares of its common stock at an exercise price of $3.76 per share of common stock, at a combined public offering price of $3.00 per share of common stock and accompanying warrant. |
prnewswire.com |
2024-12-13 09:00:00 |
Czytaj oryginał (ang.) |
| INOVIO Announces Proposed Public Offering |
PLYMOUTH MEETING, Pa. , Dec. 12, 2024 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it intends to offer and sell shares of its common stock and accompanying warrants to purchase shares of its common stock, in an underwritten public offering. |
prnewswire.com |
2024-12-12 18:01:00 |
Czytaj oryginał (ang.) |
| New Retrospective Data Shows Half of RRP Patients Treated with INO-3107 Achieved a Complete Response When Evaluated 2 and 3 Years Following Initial Phase 1/2 Trial |
Data from a retrospective trial evaluating the longer-term benefit of INO-3107 to patients with Recurrent Respiratory Papillomatosis (RRP) involved in a Phase 1/2 trial showed the number of patients who met the criteria for a Complete Response (CR) increased to 50% by the end of year 2 and to 54% in year 3, compared to 28% by the end of the initial 52-week trial 95% of patients in the retrospective trial (RRP-002) maintained or enhanced their original Overall Response Rate (ORR) reported in the Phase 1/2 trial (RRP-001) by the end of year 2; 86% of patients maintained or enhanced ORR into year 3 New durability data will help inform re-dosing strategy focused on long-term elimination or reduction in the need for surgery to treat RRP disease INOVIO plans to present data at future scientific conferences and submit for publication in peer-reviewed journals PLYMOUTH MEETING, Pa. , Dec. 3, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced data from a retrospective trial showing that the number of RRP patients meeting the criteria for a Complete Response increased to 50% by the end of the second year following initial treatment with INO-3107 in a previously reported Phase 1/2 52-week trial where the Complete Response rate was 28%. |
prnewswire.com |
2024-12-03 10:00:00 |
Czytaj oryginał (ang.) |
| INOVIO Reports Inducement Grant Under Inducement Plan |
PLYMOUTH MEETING, Pa. , Nov. 29, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it has made an equity grant to a newly hired employee under its 2022 Inducement Plan (the "Inducement Plan"). |
prnewswire.com |
2024-11-29 18:02:00 |
Czytaj oryginał (ang.) |
| European And US Vaccine Stocks Are Under Pressure - Here's WHy |
Some large European and U.S. vaccine maker stocks have fallen in reaction to Robert F. Kennedy Jr.'s nomination to lead the Department of Health and Human Services. |
benzinga.com |
2024-11-15 13:21:18 |
Czytaj oryginał (ang.) |
| Inovio Pharmaceuticals, Inc. (INO) Q3 2024 Earnings Call Transcript |
Inovio Pharmaceuticals, Inc. (NASDAQ:INO ) Q3 2024 Earnings Call Transcript November 14, 2024 4:30 PM ET Company Participants Thomas Hong - Manager of IR Jacqui Shea - President and CEO Mike Sumner - CMO Steve Egge - CCO Peter Kies - CFO Matthew Morrow - VP of Translational Sciences Conference Call Participants Jay Olson - Oppenheimer Roy Buchanan - Citizens JMP Sudan Loganathan - Stephens Liang Cheng - Jefferies Operator Good afternoon, ladies and gentlemen, and welcome to the Inovio Third Quarter 2024 Financial Results Conference Call. At this time, all lines are in a listen-only mode. |
seekingalpha.com |
2024-11-14 21:53:10 |
Czytaj oryginał (ang.) |
| INOVIO Reports Third Quarter 2024 Financial Results and Recent Business Highlights |
New immunology data for INO-3107 supporting proposed mechanism of action presented at several recent conferences Data showed ability of INO-3107 to induce an antigen-specific cytotoxic T cell response against HPV-6 and HPV-11 and drive recruitment of T cells into airway tissues and papilloma Data showed INO-3107 induced expansion of new clonal T cells that infiltrate airway tissues and correspond with reduction of surgeries for RRP patients observed in Phase 1/2 trial Continued progress on preparing regulatory submissions for INO-3107 All non-device BLA modules on track for completion by end of 2024 BLA submission remains targeted for mid-2025 PLYMOUTH MEETING, Pa. , Nov. 14, 2024 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced its financial results for the third quarter of 2024 and provided an update on recent company developments. |
prnewswire.com |
2024-11-14 18:05:00 |
Czytaj oryginał (ang.) |
| Immunology Data Shows INOVIO's INO-3107 Induced Expansion of New Clonal T Cells That Infiltrate Airway Tissue and Correspond With Reduction of Surgeries for RRP Patients Observed in Phase 1/2 Trial |
New immunology data shows INO-3107 induced an expansion of new clonal T cells in blood that were not detectable prior to treatment New clonal T cells in the blood travelled to papilloma and airway tissues and generated an inflammatory and anti-viral response consistent with a reduced need for surgeries for patients with recurrent respiratory papillomatosis (RRP) caused by HPV-6 and HPV-11 Data supporting mechanism of action for INO-3107 to be presented at 36th International Papillomavirus Conference in Edinburgh, UK PLYMOUTH MEETING, Pa. , Nov. 13, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced new immunology data that supports the clinical activity of its lead product candidate, INO-3107, that was previously observed in a Phase 1/2 trial of RRP patients. |
prnewswire.com |
2024-11-13 10:00:00 |
Czytaj oryginał (ang.) |
| INOVIO to Present at Upcoming Scientific Conferences |
PLYMOUTH MEETING, Pa. , Nov. 6, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it will present at the following scientific conferences: 36th International Papillomavirus Conference (Edinburgh, UK; November 12-15) Presentation and poster by Dr. Matthew Morrow, VP of Translational Sciences Abstract Title: Treatment of recurrent respiratory papillomatosis with INO-3107 induces significant enrichment in hallmark interferon alpha, interferon gamma and inflammatory molecular signatures in papilloma tissue of responders Poster by Dr. Jeffrey Skolnik, SVP of Clinical Development Abstract Title: Clinical response to INO-3107 treatment for recurrent respiratory papillomatosis is associated with CD4 and CD8 T-Cell activity and cytotoxicity in patient airways Vaccines Summit (Boston, MA; November 13-15) Keynote presentation by Dr. Dave Liebowitz, SVP Early-Stage Clinical Development Abstract Title: DNA Medicines Vaccine Platform for both Prophylactic and Therapeutic Applications: Case Studies in Ebola and Recurrent Respiratory Papillomatosis Abstracts from these conferences will be made available on INOVIO's website following each presentation. |
prnewswire.com |
2024-11-06 18:05:00 |
Czytaj oryginał (ang.) |
| INOVIO to Report Third Quarter 2024 Financial Results on November 14, 2024 |
PLYMOUTH MEETING, Pa. , Nov. 6, 2024 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer, and infectious diseases, today announced that third quarter 2024 financial results will be released after the market close on November 14, 2024. |
prnewswire.com |
2024-11-06 10:00:00 |
Czytaj oryginał (ang.) |
| INOVIO Announces New Data at Scientific Conferences for Lead Candidate, INO-3107, as a Potential Treatment for RRP |
American Association for Cancer Research (AACR) Special Conference: Tumor Immunology and Immunotherapy : New immunology data showed ability of INO-3107 to induce an antigen-specific T cell response against HPV-6 and HPV-11 and drive recruitment of T cells into airway tissues and papilloma International Society of Vaccines Conference : Full safety and efficacy data from Phase 1/2 clinical study in patients with Recurrent Respiratory Papillomatosis (RRP) indicated that INO-3107 was well tolerated and immunogenic; 81% of patients in the trial required fewer surgeries post-treatment when compared to baseline PLYMOUTH MEETING, Pa. , Oct. 21, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced the presentation of new data at scientific conferences for its lead candidate, INO-3107, for which the company is preparing a Biologics License Application for targeted submission in mid-2025 under the U.S. Food and Drug Administration's Accelerated Approval Pathway Program. |
prnewswire.com |
2024-10-21 12:00:00 |
Czytaj oryginał (ang.) |
| Inovio (INO) Surges 6.8%: Is This an Indication of Further Gains? |
Inovio (INO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term. |
zacks.com |
2024-10-09 10:41:13 |
Czytaj oryginał (ang.) |
| INOVIO Reports Inducement Grants Under Inducement Plan |
PLYMOUTH MEETING, Pa. , Oct. 2, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it has made equity grants to certain employees under its 2022 Inducement Plan (the "Inducement Plan"). |
prnewswire.com |
2024-10-02 20:15:00 |
Czytaj oryginał (ang.) |
| INOVIO to Present at Upcoming Scientific Conferences |
PLYMOUTH MEETING, Pa. , Oct. 1, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it will present at the following scientific conferences: AACR Special Conference in Cancer Research: Tumor Immunology and Immunotherapy Poster by Dr. Matthew Morrow, VP of Translational Sciences at INOVIO Abstract Title: Reduction in Surgical Interventions for the Treatment of Recurrent Respiratory Papillomatosis by INO-3107 is Associated with Enriched Macrophage, Dendritic cell and T cell Signatures in Patient Airways Date and Time: October 19, 2024, 6:00 - 8:15pm ET Location: Boston, MA ISV Congress 2024 Oral presentation and poster by Dr. Michael Sumner, Chief Medical Officer at INOVIOAbstract Title: Clinical Assessment of Adjuvant Immunotherapy, INO-3107, in Adult Patients with Recurrent Respiratory Papillomatosis (RRP) Date and Time: October 22, 2024, 4:20pm KSTLocation: Seoul, Korea Fall Voice Poster by Dr. Jeffrey Skolnik, SVP of Clinical Development at INOVIOAbstract Title: Clinical Assessment of Adjuvant Immunotherapy, INO-3107, in Adult Patients with Recurrent Respiratory Papillomatosis (RRP) Date and Time: October 25 – October 26, 2024 Location: Phoenix, AZ World Vaccine Congress Europe Presentation and panel discussion by Dr. Dave Liebowitz, SVP Early-Stage Clinical Development at INOVIOTrack: Pre-Congress Workshop on Platform TechnologiesDate and Time: October 28, 2024, 10:00am CET Location: Barcelona, Spain Abstracts from these conferences will be made available on INOVIO's website following each presentation. |
prnewswire.com |
2024-10-01 12:00:00 |
Czytaj oryginał (ang.) |
| INOVIO to Present at Upcoming Scientific Conference |
PLYMOUTH MEETING, Pa. , Sept. 17, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it will present at the following scientific conference: World Congress of Electroporation Oral Presentation by Trevor Smith, VP of Preclinical R&D at INOVIOAbstract Title: Development of in vivo-launched synthetic DNA-encoded antibodies employing CELLECTRA® electroporation technology Date and Time: September 18, 2024, 3:20pm – 3:35pm CET Location: Rome, Italy The abstract from the conference will be made available on INOVIO's website following the data presentation. |
prnewswire.com |
2024-09-17 20:30:00 |
Czytaj oryginał (ang.) |
| Inovio Pharmaceuticals, Inc. (INO) Q2 2024 Earnings Call Transcript |
Inovio Pharmaceuticals, Inc. (NASDAQ:INO ) Q2 2024 Earnings Conference Call August 8, 2024 4:30 PM ET Company Participants Thomas Hong - Manager of Investor Relations Jacqueline Shea - President & Chief Executive Officer Steve Egge - Chief Commercial Officer Michael Sumner - Chief Medical Officer Peter Kies - Chief Financial Officer Conference Call Participants Anish Nikhanj - RBC Capital Markets Roy Buchanan - Citizens JMP Jay Olson - Oppenheimer Sudan Loganathan - Stephens Yi Chen - H.C. Wainwright Operator Good afternoon ladies and gentlemen and welcome to the Inovio Second Quarter 2024 Financial Results Conference Call. |
seekingalpha.com |
2024-08-09 07:32:07 |
Czytaj oryginał (ang.) |
| INOVIO Reports Second Quarter 2024 Financial Results and Recent Business Highlights |
PLYMOUTH MEETING, Pa. , Aug. 8, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced its financial results for the second quarter of 2024 and provided an update on recent company developments. |
prnewswire.com |
2024-08-08 20:05:00 |
Czytaj oryginał (ang.) |
| INOVIO Reports Inducement Grant Under Inducement Plan |
PLYMOUTH MEETING, Pa. , Aug. 1, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it has made an equity grant to a newly hired employee under its 2022 Inducement Plan (the "Inducement Plan"). |
prnewswire.com |
2024-08-01 20:05:00 |
Czytaj oryginał (ang.) |
| Inovio Receives Advanced Therapy Medicinal Product Certificate from European Medicines Agency for Quality and Non-Clinical Data for Lead Candidate INO-3107 |
Data reviewed complies with standards that would be used to evaluate an EU Marketing Authorization Application PLYMOUTH MEETING, Pa. , July 25, 2024 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that the European Medicines Agency's Committee for Advanced Therapies (CAT) has certified the quality and non-clinical data for INO-3107, INOVIO's lead candidate for the treatment of Recurrent Respiratory Papillomatosis (RRP). |
prnewswire.com |
2024-07-25 20:05:00 |
Czytaj oryginał (ang.) |